LBT Innovations wins crucial European approvals

Medical technology developer LBT Innovations (ASX: LBT) has won European CE mark certification for its APAS Independence laboratory instrument, allowing sale in all European countries.

The company has identified 130 priority customers among laboratories in Europe, and will follow its successful strategy of placing its instruments with the laboratories for performance evaluation.

APAS is an artificial intelligence (AI) based digital technology for automated imaging of medical culture plates used to diagnose infection.

And the APAS Independence (pictured), already on sale in Australia, is an imaging, interpretation, sorting and reporting system that automatically examines culture plates for the presence of bacterial colonies.

The machine automatically finds culture plates which show no sign of infection, freeing up microbiologists for more important tasks.

LBT’s CEO Brent Barnes said: “CE marking for the APAS Independence is an important step towards completing the company’s market launch strategy to have a regulatory cleared instrument available for sale in Australia, the EU and the USA.

“It provides customers in the EU with further technology validation and provides the calyst to build on our sales activities in the region.”

LBT’s head office and software and hardware product development laboratories located in Adelaide have taken a number of instruments to market.

Clever Culture Systems AG (CCS), a joint venture between LBT and Hettich Holding Beteiligungs- und Verwaltungs-GmbH (Hettich), has had responsibility for manufacturing the APAS Independence since 2013.

Picture: LBT Innovations/APAS Independence

Subscribe to our free @AuManufacturing newsletter here.

Share this Story

Stay Informed

Go to Top